𝔖 Bobbio Scriptorium

✦ LIBER ✦

Effects of the D-1 agonist SKF-38393, combined with haloperidol, in schizophrenic patients: A preliminary report

✍ Scribed by Davidson, Michael; Harvey, PhilD.; Powchik, Peter; Goddard, AndrewW.; Bergman, R.Lindsey; Davis, KennethL.

Book ID: 122474277
Publisher: Elsevier Science
Year: 1989
Tongue: English
Weight: 69 KB
Volume: 2
Category: Article
ISSN: 0920-9964
DOI: 10.1016/0920-9964(89)90236-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of the D-1 agonist SKF-38393, co

Effects of the D-1 agonist SKF-38393, combined with haloperidol, in schizophrenic patients: A preliminary report

✍ M. Davidson; P. Harvey; P. Powchik; A. Goddard; R. Bergman; K. Davis 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Neurobehavioral effects of prenatal expo

Neurobehavioral effects of prenatal exposure to AZT: a preliminary investigation with the D1 receptor agonist SKF 38393 in mice

✍ Aldina Venerosi; Angelina Valanzano; Maria Puopolo; Gemma Calamandrei 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Combination of a δ opioid receptor agoni

Combination of a δ opioid receptor agonist but not a μ opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice

✍ Tohru Toyoshi; Makoto Ukai; Tsutomu Kameyama 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 447 KB

The effects of atromid on serum choleste

The effects of atromid on serum cholesterol, serum triglycerides, and radioactive fat tolerance in patients with hyperlipidemia. a preliminary report

✍ D. Berkowitz 📂 Article 📅 1963 🏛 Elsevier ⚖ 187 KB

9148 Phase 1 study of the toll-like rece

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

✍ Smith, D.A.; Conkling, P.; Richards, D.; Alemany, C.; Boyd, T.; Garbo, L.; Wu, H 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

40 KDA peginterferon alfa-2A (PEGASYS®)

40 KDA peginterferon alfa-2A (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with HCV genotype 1: a preliminary report of a comparative, multicenter, efficacy and safety study: Lennox J Jeffers, Miami VA Medical Center, Miami, FL; William Cassidy, Louisiana State University Health Sciences Center, Baton Rouge, LA; Charles Howell, University of Maryland School of Medicine, Baltimore, MD; K. Rajender Reddy, University of Miami School of Medicine, Miami, FL; Michael Fallon, University of Alabama, Birmingham, AL; Michael Dragutsky, Gastroenterology Center of the MidSouth, PC, Memphis, TN; George E Harb, Talia Biran, Roche Laboratories Inc, Nutley, NJ

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB